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This thesis considers the aspects of therapeutics development for Cystic Fibrosis (CF).  The 
studies are directed at the development of a new therapeutic outcome measurement for 
evaluating the performance of CF medications.  This imaging-based outcome measures the 
absorption of a small-molecular radiopharmaceutical, Diethylene triamine pentaacetic acid 
(DTPA) from the airways as a surrogate measure of liquid absorption.  Airway liquid hyper-
absorption is a key aspect of CF lung disease that would be expected to correct rapidly after 
administration of a successful therapy.  In vivo pilot studies of this technique have been 
previously performed at our center [1].  Here we report the results of in vitro studies performed 
to better define the mechanism underpinning our method and define its utility and limitations.   
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 AIRWAY PHYSIOLOGY & ANATOMY  
The lungs are the site of gas exchange during respiration.  The nose and mouth are connected 
to the trachea, which branches into two bronchi that enter the left and right lungs.  Successive 
generations of airways, increasing in number while decreasing in size, branch from the bronchi 
peripherally to provide a path for air to enter and exit the lungs.  The terminal branches of the 
bronchi are called the bronchioles.  Each of these divides into 2-11 alveolar ducts.  From each 
alveolar duct, 5-6 alveolar sacs are formed.  There are approximately 300 million alveoli in each 
lung which are covered with capillary sheet and are the site of gas exchange [2]. 
The epithelia of the large airways are covered with cilia, which are hair-like projections that 
move in a synchronous manner, and a thin layer of mucus.  The mucus and cilia are part of the 
body‟s innate immune system and act as a first defense against inhaled pathogens to prevent 
infections.  The mucus traps pathogens and the cilia propel them out of the respiratory tract.  
This process is called mucociliary clearance (MCC).  Pathogens smaller than 0.6nm will be able 
to evade MCC and can be absorbed via the bronchial epithelia into the bloodstream[3].   
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Figure 1  Comparison of a healthy epithelial cell on the left versus a CF epithelial cell on the right.  
The green protein channels signify the CFTR protein with the green squares representing chloride ions being 
secreted.  The red protein channels represent the ENaC protein with the red dots representing sodium ions 
being absorbed.  In the healthy epithelial cell on the left, there is a balance of ions being secreted and 
absorbed creating an isotonic ASL.  On the right the CFTR channel is defective, causing an imbalance of ions 
in the ASL which causes the ASL to hyperabsorb creating a layer of thick immobile mucus. 
 
A thin watery layer of liquid called the periciliary layer (PCL) bathes the cilia and has 
approximately the same height.  The mucus lies on top of the cilia and PCL.  The tonicity of the 
PCL layer is maintained by ion channels that control sodium absorption and chloride secretion 
[4-5].  Sodium is absorbed via the epithelial sodium channel (ENaC).  Chloride is secreted via 
both the cystic fibrosis transmembrane regulator (CFTR) and alternate Calcium activated 
chloride channels (CaCC)[6].  The CFTR ion channel is associated with the basic defect of CF, 
and  is part of the family of channels called ATP binding cassette transporters (ABC 
transporter)[7].  The balance of sodium and chloride ions maintains the osmotic homeostasis in 
the airway surface liquid layer (ASL).  If tonicity is disrupted, as would occur with evaporation 
or liquid volume addition to the airway, the ASL will either absorb or expand via transcellular 
and paracellular pathways to regain the isotonic layer height of the PCL as shown in Figure 1.   
There are multiple liquid transport routes through the airway epithelium.  In transcellular 
transport, liquid is moved through the cell down the osmotic gradient via a family of water 
protein channels imbedded in the lipid bilayer membrane of cells called aquaporins (AQPs).  A 
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variety of aquaporins are found throughout cells in the body.  Aquaporins AQP1, AQP3, AQP4 
and AQP5 are found exclusively in the lungs and airways [8].  Paracellular transport involves the 
passage of liquid through the intercellular gaps.  This process is driven by the osmotic gradient 
[9].  Tight junctions hinder this pathway by connecting neighboring cells together to create a 
virtually impassible barrier.  Not all epithelia contain tight junctions.  Epithelia that are 
considered to be „leaky‟ are missing or have weak tight junctions and fluid is able to pass 
through the intercellular gaps. 
Solute transport also occurs via transcellular and paracellular mechanisms.  The transcellular 
protein channels that are used to transport fluids such as AQPs cannot be used for solute 
movement.  Protein channels in the cell bilayer allow for the transport of specific molecules.  If 
the solute does not have a protein channel then transcellular transport is not possible.  Unless the 
solute is able to passively diffuse through the lipid bilayer of the cells.  Diffusion through the 
lipid bilayer of the cells depends on the solute‟s polarity and molecular size.  Paracellular 
transport of solutes is the same as the mechanism for liquids.  Phenomena such as solvent drag 
improve solutes ability to transport across the epithelia.  Solvent drag occurs when the flow of a 
fluid forces solvents to follow the direction of the fluid.  In the case of cellular transport if the 
direction of fluid flow is towards the epithelia from the ASL, it can transport solute to the 
epithelia where it can undergo transcellular or paracellular mechanisms depending on the solute 
particle.  
1.2 CYSTIC FIBROSIS LUNG DISEASE 
1.2.1 ASL Volume Regulation 
Cystic fibrosis (CF) is an autosomal recessive disease that affects the lungs, liver, 
intestine, sinuses, skin, and reproductive systems.  It is related to a single defective gene, the 
CFTR gene, which is responsible for encoding the CFTR protein in the epithelial cells. It can 
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mutate, rendering the CFTR protein ineffective to varying degrees depending on the severity of 
the mutation [10].   
A defect classification system has been devised to group CFTR mutations depending on 
the effect of the mutation of production and transport of the CFTR protein (Class I-V) [11].  The 
main mutations found in CF patients are: defective protein production (Class I), abnormal 
intracellular trafficking (Class II), defective chloride transport (Class III), reduction in chloride 
transport (Class IV) and reduced protein expression of protein but normal function (Class V) 
[12].  The most common CFTR mutation is a Class II defect involving the deletion of the amino 
acid phenylalanine at position 508 on the CFTR gene.  This defect known as F508 accounts for 
70% of mutant alleles and causes the most common form of cystic fibrosis [12]. 
As previously described, CFTR is an epithelial ion channel responsible for the secretion 
of chloride ions while ENaC is responsible for the absorption of sodium ions. Together CFTR 
and ENaC maintain the isomolarity of the ASL.  By regulating the concentration of chloride and 
sodium ions on the luminal surface of the airway epithelium, CFTR and ENaC influence the flux 
of water across the epithelium.  When the CFTR is ineffective, chloride ions are not secreted 
resulting in an imbalance of ions in the ASL causing it to become hypotonic.  Sodium hyper-
absorption through ENaC has also been reported on the CF airway epithelium [5, 13-14], further 
contributing to airway hypotonicity.  To compensate for the hypotonic ASL, the PCL is absorbed 
until a homeostatic balance is reached.  This results in a loss of water from the mucus that lines 
the airways causing it to become hardened and dehydrated. Therefore, dehydrated mucus in the 
airways is a symptom of CF. 
Dehydrated mucus in the airways increases the proclivity for chronic lung infections [15].  
Mucus clearance is a key host defense for the lungs that prevents opportunistic infections.  CF 
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patients have a higher risk for bacterial infections by opportunistic pathogens such as 
Pseudomonas aeruginosa [16].  The height of the PCL in a healthy airway is approximately the 
height of the extended cilia ~7 μm [17].  In the case of CF patients, the PCL is hyper absorbed to 
~4μm.  This liquid height collapses the cilia, preventing them from playing their normal role in 
mucus clearance leaving a layer of thick immobile mucus as well as exposing the cilia of the 
lung epithelia [5].   
1.2.2 Cystic Fibrosis Therapeutics 
A variety of therapies are available for the treatment of CF.  Focusing on the chronic lung 
infections linked to cystic fibrosis, there are two approaches in treating CF, prophylactic and 
symptom based treatment.  Symptom based therapy fights the opportunistic infections as they 
occur, while prophylactic therapy seeks to prevent or reduce the number of infections by treating 
the underlying pathophysiology of CF.   
The treatment of disease progression is still the mainstay of available therapies in CF.  
Due to the fact that CF patients tend to have chronic infections, symptom based therapies are 
often used as prophylactic therapies too.  For example, antibiotics typically used to treat a lung 
infection would be prescribed for the current infection and the patient would continue on it to 
prevent further infections.  A common example is the inhalation of the aminoglycoside antibiotic 
tobramycin, which is frequently used to treat bacterial infections such as P. aeruginosa [18].   
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Table 1  Pathophysiology of CF with the comparison of biomarkers and therapies.  The center 
column shows the progression of CF from the basic elements to serious conditions of the disease.  The right 
column shows where current treatments are targeting the pathophysiology and the left column shows how 
which stage Outcome Measures measure the effectiveness of the therapy. 
 
Outcome measures or 
Biomarkers  
Pathophysiology  Therapies 
 
Defective CFTR  
Gene therapy  
Nasal Potential  
Difference  
Improper ion fluxes  sodium channel blockers, alt 
chloride agonists  
Absorptive or 2 isotope 
clearance scan  
Improper fluid fluxes  
Hypertonic saline  
 
Thinned, viscous ASL  
 
Mucociliary scans  
Defective clearance  
 
Serum cytokines, Exhl Br 
Condensate, Exhl Gas  
Infection, Inflammation  Antibiotics,   
Anti-inflammatory  
CT scan  
Mucus plugging, airway damage  
Dnase  
Pulmonary function  
Loss of pulmonary function  
 
Exacerbations, QOL  
Loss of QOL, mortality  
  
 
Recent therapeutic development efforts in CF have been directed at the most basic 
elements of CF lung disease as shown in Table 1.  This includes the development of gene therapy 
techniques to correct the CFTR gene,  CFTR “correctors” which repair specific intracellular 
processes associated with CFTR production and transport, CFTR “potentiators” which assist the 
function of defective CFTR that is available at the epithelial surface, channel modulators which 
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correct sodium and chloride flux at the epithelium, and osmotics which drive water transport 
towards the airway lumen to rehydrate the ASL [19]. 
Current treatments for CF include therapies that modify the ASL such as inhaled 
hypertonic saline [20-21].  Hypertonic saline reverses the osmotic gradient at the epithelium, and 
increases the liquid content of the ASL to the levels similar to those seen in healthy subjects.  
Along with osmotic therapies there are 2 different CFTR modulating drugs are in phase 3 testing, 
VX-770 from Vertex Pharmaceutical and Ataluren (formerly known as PTC124) from PTC 
Therapeutics [22-24].   
A crucial research area in CF therapy development is outcomes development.  Most 
current clinical methods used to determine the efficacy of CF therapies require months of 
treatment and observation before measureable changes can be detected [25].  New methods for 
determining the efficacy of therapies designed to treat the most basic aspects of CF lung disease 
would increase the speed with which therapies could be made available to patients [26].  As 
recent therapies focus on rehydrating the ASL, an outcome measure that has the ability to gauge 
liquid absorption in airways would be a significant improvement. 
This project involves the development of an imaging based outcome measure for use in 
testing new CF therapies.  Specifically in vitro studies were performed in airway cell cultures to 
help determine the suitability of a radiopharmaceutical for measuring airway liquid absorption.   
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2.0  OUTCOME MEASUREMENT DEVELOPMENT:  TWO ISOTOPE IN VITRO 
STUDIES 
2.1 BACKGROUND 
2.1.1 In vivo study – Previous work 
We have previously performed a small clinical study using an aerosol based imaging 
method.  Our previous work  used a 2 isotope model to measure the absorptive clearance rate of 
DTPA between CF and control subjects  to see if it can be used as a possible early outcome 
measure [1].  The use of two different isotopes, TC99m-Sulfur Colloid (SC) and In111-DTPA, 
allowed us to measure the clearance based on MCC and absorption.  The TC99m-SC isotope can 
only be cleared via MCC and the In111-DTPA isotope can be cleared via both MCC and 
absorptive pathways, therefore by subtracting the clearance rate of TC99m-SC from the 
clearance rate of the In111-DTPA, the absorptive clearance of the DTPA can be calculated.  In 
our 2 isotope pilot study we found that there was a difference in the absorptive clearance of 
DTPA in CF and nonCF patients as shown in Figure 2.   
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Figure 2  Absorptive clearance in central and peripheral lung zones.  The dark circles are the CF 
cases n=9 and the open circles are the nonCF cases n=10. 
2.1.2 DTPA Transport 
We have considered the possibility of using a small molecule radiopharmaceutical as a 
surrogate for measuring liquid absorption in the airways.  One option with a significant safety 
history in the lung is diethylene triamine pentaacetic acid (DTPA).  There are two FDA approved 
radiolabeled forms of DTPA available, Technetium 99m-DTPA (Tc-DTPA) and Indium 111-
DTPA (In-DTPA).  DTPA is a small negatively charged hydrophilic molecule with a molecular 
weight 393.35 g/mol.  Liquid transport through the epithelium occurs through both transcellular 
and paracellular routes.  Paracellular transport has long been the assumed only pathway for 
DTPA transport through the epithelium since transcellular route are generally impermeable to 
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small solute [27-29].  We hypothesized that DTPA absorption might be influenced via a solvent 
drag mechanism, by the paracellular component of airway liquid absorption, and might provide a 
gauge of the paracellular absorption rate.  As previously described CF lung disease is associated 
with liquid hyper-absorption.  In vitro studies have demonstrated that liquid added to the 
epithelial surface of a CF airway is absorbed more rapidly than in a normal airway.  Rectification 
of the basic defect of CF lung disease should result in rapid correction of this effect.  Though the 
exact balance between the transcellular and paracellular components of liquid absorption in the 
CF airway is unknown, we hypothesized that therapeutic correction would result in detectable 
changes in paracellular transport that would be proportional to changes in overall liquid 
absorption in the airway.  Studies in the intestine have previously demonstrated relationships 
between paracellular liquid transport and the absorption rate of small solutes [30].   
An alternative hypothesis is that the inflammatory disease damages the bronchial 
epithelia creating sites of increased permeability via epithelial denuding or eroding of the 
epithelial and by cytokines reducing tight junction permeability [31-34].  The inflammation 
causes the epithelia to become „leaky‟ and increases the DTPA transport through the tight 
junctions.  Studies have shown that smokers show increased clearance of DTPA [33].  It was also 
found that asthma patients had increased DTPA clearance[35].   
We hypothesize that DTPA transport across the epithelia is due to a phenomenon known 
as solvent drag [36].  Normally when particles and solvent are present in a system, the movement 
of the solvent causes the particles to flow along with the solvent.  In the case of CF, the 
hyperabsorption of the ASL causes water to move from the apical surface towards the basolateral 
surface, thus dragging the hydrophilic DTPA molecule towards the epithelia where it is assumed 
to be absorbed via paracellular pathways.   
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As previously described the CF airway hyper-absorbs liquid due to the errant transport of 
sodium and chloride ions associated with mutations in the CFTR gene [13, 16, 37].  This hyper-
absorption could cause an increase in DTPA absorption and explains the difference in 
absorptions rates observed in our previous study involving 2 isotopes [1]. 
2.2 SPECIFIC AIMS 
Outcome measures are critical in determining drug efficacy in a timely manner.  In the 
case of cystic fibrosis, early stage outcome measures are crucial as many new therapies target the 
basic elements of the disease while most available outcome measures quantify effects of later 
stage disease progression.  One of the main goals of these new therapies is to treat the 
hyperabsorption of liquid in the airways-a key basic element of CF lung disease. We have 
previously performed clinical studies of a potential radiopharmaceutical surrogate for measuring 
liquid absorption in the airways [1].  
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2.2.1 Aim 1: To explore the feasibility of DTPA absorption as a clinical outcome measure 
for testing CF therapies using human bronchial epithelia cells (HBEs) to mimic the 
functional imaging technique we have piloted in our CF patients. 
2.2.1.1  Hypothesis 1: DTPA absorption will be increased in primary human bronchial epithelial 
cultures derived from explanted cystic fibrosis lungs when compared to non-CF lungs.  To test 
this hypothesis we measured the absorption of radiolabeled DTPA in CF and non-CF HBE’s 
over 24 hours.   
2.2.1.2 Hypothesis 2:  DTPA absorption will be driven by osmotic gradients in a manner similar 
to liquid absorption.  To test this hypothesis varying concentrations of an osmolar agent, 
mannitol, were added to the apical or basolateral surfaces of CF and non-CF HBEs and the 
absorption of radiolabeled DTPA was measured over 24 hours.  
2.2.1.3 Hypothesis 3: Human bronchial epithelial cells treated with pro-inflammatory cytokines 
will demonstrate increased rates of DTPA absorption in association with increased tight junction 
diameter.  To test this hypothesis cytokines were added to the basolateral surface of CF and non-
CF HBEs and the absorption of radiolabeled DTPA was measured for 24 hours.   
2.2.1.4 Hypothesis 4:  DTPA absorption rate can be directly related to liquid absorption rate.  To 
test this hypothesis DTPA clearance was measured using radioisotope techniques and water 
absorption was measured utilizing dye concentration-based techniques.   
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2.3 RESEARCH DESIGN:   
2.3.1 Aim 1 
The Human Bronchial epithelial cell model: 
HBE cell cultures are a high fidelity model of the luminal surface of an airway.  These 
cultures exhibit normal airway physiology including ion conductance, liquid transport, mucus 
generation, and ciliary motion.  CF cell lines exhibit the ion and liquid transport defects seen in 
CF patients.  The cell lines are not immortalized and their availability is dependent on recent 
transplant activity.  Contemporary controls are utilized throughout the experiments.  Controls 
designated as „non-CF‟ have been generated from lungs with disease states not thought to 
substantially impact normal airway physiology as illustrated in culture.  The specific cell lines 
used in these experiments along with the associated disease conditions resulting in 
transplantation are shown in Table 2.   
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Table 2: Cell lines with corresponding conditions leading to transplant 
Cell Line Disease  
HBE 655 Idiopathic pulmonary fibrosis (IPF) 
HBE 675 Immotile cilia 
HBE 665 Emphysema 
HBE 666 Emphysema 
CF 150 Cystic Fibrosis ΔF508/D1152H (Class IV) 
CF 153 Cystic Fibrosis ΔF508/ΔF508 (Class II) 
 
Primary HBE cells were harvested from lungs removed at the time of lung transplant 
from CF and other advanced lung diseases according to a University of Pittsburgh Institutional 
Review Board approved protocol.  As previously described [38] airway sections from these lungs 
were digested in a protease solution to detach the epithelial cells.  The epithelial cells were then 
resuspended in a 1:1 bronchial epithelial growth media/keratinocyte-serum free medium 
(BEGM/K-FSM) and seeded onto sterile tissue flasks precoated with human placental collagen 
for 5-6 days.  The cells were then seeded onto 1.13 cm
2
 collagen-coated transwell filters (0.4μm 
pore size, Corning-Costar Transwell Collagen T-cols, Acton, MA) at an approximate density of 2 
x 10
6
 /cm
2
.  The cells were grown on the filters for 4 weeks; once a confluent monolayer was 
reached the HBE filters were ready for experiments as shown in Error! Reference source not 
found.. The apical surface of the HBE filters were washed twice the night before the experiment 
with 100μL 1xPBS and aspirated.  This was done to remove any uneven build up of mucus on 
the apical surface.   
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Figure 3  Schematic of HBE culture 
 
The filters were then submerged in DMEM, 550 μL basolateral surface, 250 μL on the 
apical in preparation for measuring the potential difference across the filter.  The filters were 
submerged for approximately 15minutes.  The filters were measured using a Millipore* 
Millicell-ERS Volt-Ohm Meter (Fisher Scientific #MERS00001).  Both trans-epithelial electrical 
resistance and voltage were recorded.  Each filter was measured 3 times before the DMEM was 
aspirated and the cells were returned to 0.5 % UNC/USG media overnight.  The average values 
obtained is shown in Figure 3 for the mannitol experiments.  Measuring potential difference is a 
quantifiable approach for determining confluence in filters [39].   
 
In vitro measurements of DTPA absorption 
A major element of the current experiments is the measurement of DTPA absorption rate 
in the HBE cell cultures.  In most of these studies small volumes (10 µL) of Tc-DTPA in PBS 
were added to the apical (luminal) surface of the HBE cells.  The filter containing the cells and 
the ASL can be removed from the growth medial allowing for independent measurements of 
retained radioactivity (ALS, cells, and filter) and absorbed radioactivity (media).  Filters were 
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placed in 300 μL 0.5 % UNC/USG media and 10 μL of 1xPBS Tc-99m DTPA was added to the 
apical surface.  At t=0,4,8,12 hours 50 μL of fluorinert FC-40 (F9755sigma) was added to the 
apical surface of all the filters regardless of condition tested.  Radioactive counts associated with 
Tc99m-DTPA counts were measured in both the filter and media at t=0, 2, 4,8,12 and 24 hours.  
Radioactive counts were corrected for background and decay and normalized by starting counts.  
The retention curves of radioactivity vs. time for each filter were plotted and fit to exponential 
curves.  These curves were evaluated at 24 hours and then averaged.  Two-factor ANOVAs were 
used to determine significance between cases. 
2.3.1.1  Hypothesis 1 
To compare the DTPA absorption rate between the nonCF vs. CF HBEs a total of 30 
filters from 4 nonCF lines (HBE 655, HBE 665, HBE666, HBE 675) and a total of 24 filters 
from 2 CF cell lines (CF150, CF153) were compared using the technique described in Aim 1 
above. 
2.3.1.2   Hypothesis 2 
Mannitol is sugar alcohol used as an osmolar agent in medicinal therapies.  Adding 
mannitol to the apical surface of HBEs will increase the osmolarity of the ASL creating an 
osmotic gradient that would favor liquid transport from the epithelium into the ASL.[40].  The 
addition of mannitol to the basolateral media will create an osmotic gradient favoring liquid 
absorption by the epithelium.  The effects of both apical and basolateral mannitol addition on 
DTPA absorption are considered here.  The general protocols described above were followed 
with the following modifications.  For the apical mannitol case, the filters were placed in 300 μL 
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0.5 % UNC/USG media and 10 μL of 300mM Mannitol Tc-99m DTPA was added to the apical 
surface.  Two basolateral cases are considered.  A volume of 10 μL of 1xPBS Tc-99m DTPA 
was added to the apical surface and the filters were placed in either 300 μL 150mM Mannitol 0.5 
% UNC/USG media or 300 μL 300mM Mannitol 0.5 % UNC/USG media.  A total of 30 filters 
from 4 nonCF lines (HBE 655, HBE 665, HBE666, HBE 675) and a total of 24 filters from 2 CF 
cell lines (CF150, CF153) were compared. 
Table 3  Explanation of Mannitol experiment: the 4 cases and the conditions for each 
Case Apical Conditions Basolateral Conditions 
Control 10 μL of 1xPBS Tc-99m DTPA 300 μL 0.5 % UNC/USG media 
Apical Mannitol 10 μL of 300mM Mannitol Tc-
99m DTPA 
300 μL 0.5 % UNC/USG media 
150mM 
Basolateral Mannitol 
10 μL of 1xPBS Tc-99m DTPA 300 μL 150 mM Mannitol 0.5 % 
UNC/USG media 
300mM 
Basolateral Mannitol 
10 μL of 1xPBS Tc-99m DTPA 300 μL 300mM Mannitol 0.5 % 
UNC/USG media 
 
2.3.1.3 Hypothesis 3 
Cytokines are found at sites of inflammation on the bronchial epithelia.  They have been 
shown to increase tight junction permeability in previous studies with airway cultures. [31].  In 
this work the addition of specific cytokine combinations causes a decrease in the resistances 
across the epithelia indicating „loose‟ tight junctions.  Higher levels of proinflammatory 
cytokines tumor necrosis factor α (TNF α), interleukin (IL)-8, and IL-1β as well as the soluble 
intercellular adhesion molecule (ICAM)-1 have been measured in airways of CF patients [31].  
Increased tight junction permeability is associated with the combination of TNF α and INF-γ.  It 
has been proposed that lung inflammation causes an increase DTPA clearance making Tc99m-
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DTPA aerosol is a good marker to judge the permeability of the lung epithelia[34].  By 
comparing the effects of proinflammatory cytokines has to DTPA clearance, we can determine if 
proinflammatory cytokines cause DTPA clearance or if there is already a baseline DTPA 
clearance.  As previously stated an alternative hypothesis predicts DTPA clearance is due to the 
presence of proinflammatory cytokines. 
In order to see the effect of cytokine exposure on DTPA absorption, the airway cells were 
exposed to a mixture of TNF α (10ng/ml) and INF-γ (100ng/ml) on the basolateral surface for 48 
hours [31].  In the control case no cytokines were added to the 300 μL 0.5 % UNC/USG media.  
After 48 hours, the radioisotope part of the experiment as explained in Aim 1 was performed.  A 
total of 24 filters from 1 nonCF line (HBE666) were compared. 
2.3.1.4 Hypothesis 4   
A dye based method was utilized to directly compare DTPA absorption to liquid 
absorption.  Texas Red Dextran (TRD) is a large molecule (10 kDa) non-absorbable dye.  When 
TRD is added to the ASL, liquid absorption will be reflected in changes in TRD concentration 
which can be assessed using spectrofluorometry., A 50 μL mixture of 0.25 μg/ ml Texas Red 
Dextran (TRD and TcDTPA(concentration 0.01 mCi/ml?) in 1x PBS was added apically to each 
filter.  Each filter was used for a single time point measurement.  At each time point (t=0, 2, 
4,8,12 and 24 hours) radioactive counts were measured in the filter and then a 5 μL sample was 
removed from the apical surface and placed in 96 well UV spec plate.  The sample was diluted to 
200ul with the addition of 195 μL 1xPBS.  The concentration of TRD was measured using a UV 
spectrometer.  Prior to the experiment a standard curve was plotted using the UV spectrometer 
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absorption values for known concentrations of TRD.  The measured absorption from the UV 
spectrometer was used to calculate the concentration of the TRD from the standard curve. 
With addition of Texas Red Dextran (10kD TRD), we can monitor the rate of water 
absorption in the ASL and compare it to the absorption of DTPA in the ASL.  Since TRD is too 
large to diffuse or absorb through the HBE epithelia, monitoring the concentration of TRD in the 
ASL would correlate to water transport across the epithelia.  
2.4 RESULTS 
The model used a single exponential to explain the flow and decay of Tc-DTPA during 
the course of the experiment[28].  Equation 1 explains the relationship between the change in 
mass over time versus the concentration of Tc-DTPA, where Ca is the Airway DTPA 
concentration and Cp is the blood DTPA concentration.  The concentration of Tc-DTPA in the 
blood can be assumed to be zero due to the large blood volume versus the ASL volume.  The 
constant k is equal to the surface area (S) times the permeability coefficient (P) which can 
simplify Equation 1 further to lead to Equation 3.  Breaking the airway DTPA concentration 
down in mass (m) over ASL volume (V) and ASL volume to be surface area times ASL 
thickness (T), equation 3 can be further simplified to equation 6 which when solving for mass 
leads us to the single exponential model shown in Equation 7.    
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2.4.1 Aim 1 
2.4.1.1 Hypothesis 1 
Figure 2 includes a comparison of DTPA retention vs. time in representative CF and non-
CF cell lines.  As shown in the figure DTPA retention in the CF cell line CF153 (n=6 filters) is 
decreased vs. the nonCF cell line HBE675 (n=6 filters) indicating faster clearance.  The DTPA 
retention data fit well to exponential curves with R
2
 values of 0.993 and 0.995 for the cell lines 
HBE 675 and CF 153 respectively.    
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Figure 4  Representative retention curves showing DTPA absorption in CF and nonCF cell lines over 
24 hrs (n=6 filters per line).  HBE 675 is non-CF cell line (immotile cilia) and CF 153 represents a cystic 
fibrosis with the genotype ΔF508/ΔF508.   
 
The average DTPA absorption rate at 24 hours for each filter was graphed and the results 
are shown in Figure 5.   
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Figure 5  DTPA clearance rates (24 hr) from non-CF (filled) and CF (unfilled) cell lines.  HBE 655 is 
IPF.  HBE 675 is immotile cilia, HBE 666 and HBE 675 are emphysema.  CF 150 is ΔF508/1152h (class 4 
defect; less severe disease) and CF 153 is ΔF508/ΔF508 (class 2 defect; severe disease).     
 
There were significant differences amongst the CF and non-CF lines (p<0.001 in both 
cases).  The difference found in the CF cell lines could be related to the difference in mutation. 
CF 150 is a ΔF508/1152h line.  This genotype is a milder mutation than CF 153, which is a 
ΔF508/ΔF508 line.  Comparing the nonCF cell lines with the CF cell lines p<0.001.   
In summary we observed that CF cell lines cleared the DTPA at a faster rate than the 
nonCF cell lines.    
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2.4.1.2 Hypothesis 2 
As shown in Figure 6 DTPA absorption rate varied proportionally to osmotic gradients.  
These gradients were established across the epithelium using different apical and basolateral 
mannitol concentrations Mannitol added to the apical surface, which would favor liquid transport 
into the ASL from the epithelium, slows the clearance of DTPA in comparison to the no 
mannitol control.  Whereas mannitol added to the basolateral surface, which would favor liquid 
absorption, increases the absorption of DTPA as well. 
 
Figure 6  DTPA clearance from apical surface of CF HBE’s under the influence of varying osmotic 
gradients.  Retention curves from a single CF cell line are shown (CF 153, n = 12, ΔF508/ΔF508) following an 
exponential fit.    
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The mannitol dose to effect relationship was tested with four different cell lines, two 
nonCF and two CF.  Figure 7A considers the average 24hr  clearance rate for two nonCF cell 
lines at the four mannitol concentrations tested. 
In both nonCF cell lines a linear mannitol dose to DTPA absorption effect relationship 
was demonstrated, with R
2
 values of 0.76 and 0.86 for HBE 675 and HBE 655 respectively.  A 
similar relationship was seen in the two CF cell line tested (Figure 7b) with R
2
 values of 0.907 
and 0.951 for CF 153 and CF 150 respectively.   
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Figure 7  Variation in DTPA absorption rate by osmotic gradient Panel A, includes results from 2 
non-CF cell lines.   Demonstrating the effect of osmotic on  DTPA absorption rate Panel B, includes results 
from 2 CF lines Figure 5b, on the bottom compares the percent cleared over 24 hours for CF cell lines.  HBE 
655 is IPF.  HBE 675 is immotile cilia.  CF 150 is ΔF508/1152h and CF 153 is ΔF508/ΔF508 
(A) 
(B) 
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2.4.1.3 Hypothesis 3 
The addition of TNF α (10ng/ml) and  INF-γ(100ng/ml) to the basolateral media of the 
tested cell lines mimicked the effect that pro-inflammatory cytokines would have on the tight 
junctions in bronchial epithelia.  By creating „inflammed‟ HBEs we could measure the effect 
inflammation had on DTPA absorptive clearance.  DTPA clearance rate is shown in Figure 8 for 
cytokine cases and controls.  The first set of data expressed DTPA absorptive clearance was 
significantly increased with the addition of pro-inflammatory cytokines (p =0.0104).  The 
repeated experiment showed similar results with the p= 0.0102.   
 27 
 
Figure 8  Comparison of DTPA clearance between the control case and the addition of cytokine.  
Two different sets of HBE filters used on two different test days all from the same cell line. 
2.4.1.4 Hypothesis 4   
We compared DTPA and liquid absorption in airway cell cultures using a dye based 
technique.  A large fluorescent molecule, Texas Red Dextran (TRD), in a known concentration 
of 0.25 μg/ ml was added to the apical surface and the control experiment was run.  From the 
measured TRD concentrations a volume retained curve could be plotted.  From the retention 
curves, the percent retained at 24 hours could be calculated and graphed.   
To calculate the TRD concentrations from the UV spectrometer data a standard curve 
was created as shown in Error! Reference source not found..  For the experiment each filter 
was measured only once and the value from the UV spectrometer was recorded.  Using the 
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standard curve the concentrations at each time point was calculated.  Based on the concentration 
the apical volume could be calculated from the starting volume.  
Graphing the percentage of apical volume retained at 24 hours against the percentage 
DTPA absorbed at 24 hours demonstrates a linear relationship between water transport and 
DTPA transport as shown in Figure 10.   
 
 
Figure 9  Standard curve used to calculate the concentrations for the TRD experiment. 
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Figure 10  Comparing the percentage of DTPA retained versus the apical volume retained.  The dark 
circles are nonCF HBEs and the open triangles are CF hbes.  
 
2.5 DISCUSSION 
These experiments were designed to determine if measuring the DTPA absorptive 
clearance is a feasible clinical outcome measure.  Hypothesis 1 tested if there was a difference in 
DTPA absorptive clearance in CF and nonCF HBEs when pro inflammatory cytokines were not 
present.  As hypothesized the DTPA absorptive clearance rate in CF HBEs were higher than the 
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nonCF HBE case.  This significant difference in DTPA absorptive clearance rates matches the 
trends seen in the in vivo trials.  These results support the use of DTPA as a clinical outcome 
measure.   
To further understand DTPA clearance feasibility as an outcome measure hypothesis 2 
investigated the DTPA transport mechanism by affecting the osmolarity of the ASL.  The trends 
found DTPA absorptive clearance matched the expected fluid flow patterns indicating that 
solvent drag influenced DTPA absorptive clearance rates.  If water transport from the apical 
surface to the basolateral surface was almost stopped (apical mannitol case hypothesis 2), DTPA 
absorptive clearance was also stopped.  Suggesting a paracellular pathway influenced DTPA 
clearance.   
Using a dye based technique to track the percentage of water absorbed and TC99m to 
measure the percentage of DTPA absorbed, a linear relationship was discovered between DTPA 
clearance and water transport (hypothesis 4).  As more water moves from the apical surface to 
basolateral surface, more DTPA is also transported, also showing that DTPA transport is linked 
to water transport.  Suggesting DTPA clearance is influenced by solvent drag.  When comparing 
DTPA clearance in healthy and inflamed HBEs, we saw that inflammation increases DTPA 
clearance and the healthy HBEs had a baseline clearance (hypothesis 3).  From these 
observations we can conclude DTPA clears via a paracellular pathway and effected by solvent 
drag. 
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2.6 SUMMARY 
For DTPA absorption to be a viable outcome measure we had to show that DTPA 
clearance occurs in healthy HBEs along with showing DTPA absorptive clearance is sensitive to 
detect changes due to a medication.  With the results from hypothesis 3, we saw that pro-
inflammatory cytokines increases DTPA absorptive clearance, but the healthy HBEs already had 
a baseline clearance.  In the results from hypothesis 2 the DTPA absorptive clearance could 
detect a change in concentration of Mannitol added to the basolateral surface.  Drawing from 
these results it can be concluded that DTPA absorptive clearance is a viable outcome measure.  
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